Preferred Label : Cabiralizumab;
NCIt synonyms : Anti-CSF1R FPA008;
NCIt definition : A humanized monoclonal antibody directed against the tyrosine kinase receptor colony
stimulating factor 1 receptor (CSF1R; CSF-1R), also known as macrophage colony-stimulating
factor receptor (M-CSFR) and CD115 (cluster of differentiation 115), with potential
antineoplastic activity. Upon administration, anti-CSF1R monoclonal antibody FPA008
binds to CSF1R expressed on monocytes, macrophages, and osteoclasts and inhibits the
binding of the CSF1R ligands colony-stimulating factor-1 (CSF-1) and interleukin-34
(IL-34), to CSF1R. This prevents CSF1R activation and CSF1R-mediated signaling in
these cells. This blocks the production of inflammatory mediators by macrophages and
monocytes and reduces inflammation. By blocking the recruitment to the tumor microenvironment
and activity of CSF1R-dependent tumor-associated macrophages (TAMs), FPA008 enhances
T-cell infiltration and antitumor T-cell immune responses, which inhibits the proliferation
of tumor cells. Additionally, FPA008 prevents the activation of osteoclasts and blocks
bone destruction. TAMs play key roles in immune suppression and promoting inflammation,
tumor cell proliferation and survival.;
UNII : 5FJL6W0640;
CAS number : 1613144-80-1;
Molecule name : FPA-008; FPA 008; BMS-986227;
NCI Metathesaurus CUI : CL498224;
Origin ID : C123831;
UMLS CUI : C4682409;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
